Christine Lundgren1,2, Pär-Ola Bendahl3, Maria Ekholm4,3, Mårten Fernö3, Carina Forsare3, Ute Krüger3, Bo Nordenskjöld5, Olle Stål5, Lisa Rydén6,7. 1. Department of Oncology, Region Jönköping County, Jönköping, Sweden. christine.lundgren@med.lu.se. 2. Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden. christine.lundgren@med.lu.se. 3. Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden. 4. Department of Oncology, Region Jönköping County, Jönköping, Sweden. 5. Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. 6. Department of Clinical Sciences Lund, Division of Surgery, Lund University, Lund, Sweden. 7. Department of Surgery, Skåne University Hospital, Malmö, Sweden.
Abstract
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are of important prognostic and predictive value in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC), but their clinical relevance in oestrogen receptor-positive/HER2-negative (ER+/HER2-) remains unknown. The primary study aim was to analyse the prognostic effect of TILs on the BC-free interval (BCFi) in premenopausal patients stratified by BC subtypes. The secondary aim was to investigate if TILs are predictive of tamoxifen (TAM) benefit. METHODS: Archival tissues from primary breast tumours were collected from patients from the SBII:2pre trial, in which 564 premenopausal women were randomised to 2 years of adjuvant TAM or no systemic treatment, regardless of hormone receptor status. TILs were scored on whole tissue sections from 447 patients with available ER status. Tumours were divided into ER+/HER2-, HER2+ and TNBC subtypes by immunohistochemistry and in situ hybridisation. The prognostic value of TILs was analysed in systemically untreated patients (n = 221); the predictive information was investigated in the ER+ subgroup (n = 321) by cumulative incidence curves and Cox regression analyses. The median follow-up was 28 years. RESULTS: High (≥ 50%) infiltration of TILs was a favourable prognostic factor in terms of BCFi (univariable analysis: hazard ratioBCFi (HRBCFi) 0.40; 95% confidence interval (CI) 0.22-0.71; P = 0.002). Similar effects were observed across all BC subtypes. The effect of adjuvant TAM was stronger in patients with ER+ tumours and TILs < 50% (HRBCFi 0.63; 95% CI 0.47-0.84; P = 0.002) than in patients with high immune infiltration (≥ 50%) (HRBCFi 0.84; 95% CI (0.24-2.86); P = 0.77). However, evidence for differential effects of TAM in categories of TILs, i.e. interaction, was weak. CONCLUSIONS: We demonstrate a long-term favourable prognostic value of high infiltration of TILs in a cohort of premenopausal BC patients and the positive prognostic effect was extended to the ER+/HER2- subgroup. A beneficial effect of TAM in ER+ patients was observed in patients with tumours of low TIL infiltration, but evidence for a treatment predictive effect was weak. TRIAL REGISTRATION: This trial is registered in the ISRCTN database, trial ID: ISRCTN12474687 .
RCT Entities:
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are of important prognostic and predictive value in humanepidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC), but their clinical relevance in oestrogen receptor-positive/HER2-negative (ER+/HER2-) remains unknown. The primary study aim was to analyse the prognostic effect of TILs on the BC-free interval (BCFi) in premenopausal patients stratified by BC subtypes. The secondary aim was to investigate if TILs are predictive of tamoxifen (TAM) benefit. METHODS: Archival tissues from primary breast tumours were collected from patients from the SBII:2pre trial, in which 564 premenopausal women were randomised to 2 years of adjuvant TAM or no systemic treatment, regardless of hormone receptor status. TILs were scored on whole tissue sections from 447 patients with available ER status. Tumours were divided into ER+/HER2-, HER2+ and TNBC subtypes by immunohistochemistry and in situ hybridisation. The prognostic value of TILs was analysed in systemically untreated patients (n = 221); the predictive information was investigated in the ER+ subgroup (n = 321) by cumulative incidence curves and Cox regression analyses. The median follow-up was 28 years. RESULTS: High (≥ 50%) infiltration of TILs was a favourable prognostic factor in terms of BCFi (univariable analysis: hazard ratioBCFi (HRBCFi) 0.40; 95% confidence interval (CI) 0.22-0.71; P = 0.002). Similar effects were observed across all BC subtypes. The effect of adjuvant TAM was stronger in patients with ER+ tumours and TILs < 50% (HRBCFi 0.63; 95% CI 0.47-0.84; P = 0.002) than in patients with high immune infiltration (≥ 50%) (HRBCFi 0.84; 95% CI (0.24-2.86); P = 0.77). However, evidence for differential effects of TAM in categories of TILs, i.e. interaction, was weak. CONCLUSIONS: We demonstrate a long-term favourable prognostic value of high infiltration of TILs in a cohort of premenopausal BC patients and the positive prognostic effect was extended to the ER+/HER2- subgroup. A beneficial effect of TAM in ER+ patients was observed in patients with tumours of low TIL infiltration, but evidence for a treatment predictive effect was weak. TRIAL REGISTRATION: This trial is registered in the ISRCTN database, trial ID: ISRCTN12474687 .
Entities:
Keywords:
Biomarker; Breast cancer; Predictive; Premenopausal; Prognosis; TILs; Tamoxifen
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: Carsten Denkert; Gunter von Minckwitz; Jan C Brase; Bruno V Sinn; Stephan Gade; Ralf Kronenwett; Berit M Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; Peter Klare; Fabrice André; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes Journal: N Engl J Med Date: 2017-11-09 Impact factor: 91.245
Authors: Erik J Blok; Charla C Engels; Geeske Dekker-Ensink; Elma Meershoek-Klein Kranenbarg; Hein Putter; Vincent T H B M Smit; Gerrit-Jan Liefers; James P Morden; Judith M Bliss; R Charles Coombes; John M S Bartlett; Judith R Kroep; Cornelis J H van de Velde; Peter J K Kuppen Journal: Breast Cancer Res Treat Date: 2018-05-15 Impact factor: 4.872
Authors: Marcelo Sobral-Leite; Izhar Salomon; Mark Opdam; Dinja T Kruger; Karin J Beelen; Vincent van der Noort; Ronald L P van Vlierberghe; Erik J Blok; Daniele Giardiello; Joyce Sanders; Koen Van de Vijver; Hugo M Horlings; Peter J K Kuppen; Sabine C Linn; Marjanka K Schmidt; Marleen Kok Journal: Breast Cancer Res Date: 2019-08-07 Impact factor: 6.466
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Christine Lundgren; Pär-Ola Bendahl; Sarah E Church; Maria Ekholm; Mårten Fernö; Carina Forsare; Ute Krüger; Bo Nordenskjöld; Olle Stål; Lisa Rydén Journal: NPJ Breast Cancer Date: 2022-05-09